MX2019011784A - Compuestos de aril ciclopropil-amino-isoquinolinil amida. - Google Patents
Compuestos de aril ciclopropil-amino-isoquinolinil amida.Info
- Publication number
- MX2019011784A MX2019011784A MX2019011784A MX2019011784A MX2019011784A MX 2019011784 A MX2019011784 A MX 2019011784A MX 2019011784 A MX2019011784 A MX 2019011784A MX 2019011784 A MX2019011784 A MX 2019011784A MX 2019011784 A MX2019011784 A MX 2019011784A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- amide compounds
- amino
- compounds
- disclosure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
En la presente se proporcionan compuestos de arilciclopropil amino-isoquinolina amida. Particularmente, la descripción proporciona compuestos que afectan la función de quinasas en una célula que son útiles como agentes terapéuticos o con agentes terapéuticos. Los compuestos de la descripción son útiles en el tratamiento de una variedad de enfermedades y afecciones que incluyen enfermedades oculares tales como glaucoma, enfermedades cardiovasculares, enfermedades caracterizadas por crecimiento anormal, tales como cánceres y enfermedades inflamatorias. La descripción proporciona además composiciones que contienen compuestos de isoquinolina amida.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762480239P | 2017-03-31 | 2017-03-31 | |
US201862643131P | 2018-03-14 | 2018-03-14 | |
PCT/US2018/025494 WO2018183911A1 (en) | 2017-03-31 | 2018-03-30 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019011784A true MX2019011784A (es) | 2019-11-18 |
Family
ID=63678156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019011784A MX2019011784A (es) | 2017-03-31 | 2018-03-30 | Compuestos de aril ciclopropil-amino-isoquinolinil amida. |
Country Status (11)
Country | Link |
---|---|
US (3) | US10858339B2 (es) |
EP (1) | EP3609871A4 (es) |
JP (1) | JP2020515583A (es) |
KR (1) | KR20190135027A (es) |
CN (1) | CN110506037A (es) |
AU (2) | AU2018243687C1 (es) |
BR (1) | BR112019020078A2 (es) |
CA (1) | CA3057872A1 (es) |
MX (1) | MX2019011784A (es) |
SG (1) | SG11201908179UA (es) |
WO (1) | WO2018183911A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
CA2760562C (en) | 2009-05-01 | 2016-07-19 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
CN105263494A (zh) | 2013-03-15 | 2016-01-20 | 爱瑞制药公司 | 联合治疗 |
BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
US11382881B2 (en) | 2017-05-05 | 2022-07-12 | Nino Sorgente | Methods and compositions for diagnosing and treating glaucoma |
AU2018261756B2 (en) | 2017-05-05 | 2022-01-20 | Nino Sorgente | Methods and compositions for improving eye health |
WO2020056345A1 (en) * | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
WO2020176579A1 (en) * | 2019-02-26 | 2020-09-03 | Aerie Pharmaceuticals, Inc. | Thienyl cyclopropyl-amino-isoquinolinyl amide compounds |
US20230002404A1 (en) * | 2019-09-13 | 2023-01-05 | Aerie Pharmaceuticals, Inc. | Heterobicyclic carboxamides and uses thereof |
CN113072538B (zh) * | 2020-01-06 | 2024-04-05 | 广东东阳光药业股份有限公司 | RORγt抑制剂及其在药物中的应用 |
US20230149387A1 (en) * | 2020-04-08 | 2023-05-18 | Aerie Pharmaceuticals, Inc. | Treatments |
WO2023274257A1 (zh) * | 2021-07-01 | 2023-01-05 | 诸葛国琴 | 一种咪唑类化合物、其中间体及应用 |
Family Cites Families (150)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2623228C3 (de) | 1976-05-24 | 1981-09-10 | Ludwig Merckle Kg Chem. Pharm. Fabrik, 7902 Blaubeuren | N-Acyl-substituierte Benzamide, Verfahren zu ihrer Herstellung und Arzneimittel, enthaltend solche Benzamide |
JPS5587771A (en) | 1978-12-27 | 1980-07-02 | Teikoku Hormone Mfg Co Ltd | 1-phenylisoquinoline derivative |
US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
JPS5993054A (ja) | 1982-11-18 | 1984-05-29 | Asahi Chem Ind Co Ltd | イソキノリンスルホン酸アミド誘導体 |
DK8386A (da) | 1986-01-15 | 1987-07-09 | Tpo Pharmachim | Nye n-substituerede 1-benzyl-2-carbamoyltetrahydroisoquinoliner og fremgangsmaade til fremstilling af samme |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US5591887A (en) | 1987-04-30 | 1997-01-07 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
JPH01139528A (ja) | 1987-11-24 | 1989-06-01 | Showa Denko Kk | 抗潰瘍剤 |
EP1224935A3 (en) | 1988-09-06 | 2003-03-26 | Pharmacia Aktiebolag | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
DK0389995T3 (da) | 1989-03-28 | 1995-07-03 | Nisshin Flour Milling Co | Isoquinolinderivater til behandling af glaukom eller okular hypertension |
KR920008026A (ko) | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
JPH07504429A (ja) | 1992-03-12 | 1995-05-18 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5HT↓1cアンタゴニストとしてのインドール誘導体 |
US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
US6124344A (en) | 1993-12-28 | 2000-09-26 | Allergan Sales, Inc. | Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5462968A (en) | 1994-01-19 | 1995-10-31 | Allergan, Inc. | EP2 -receptor agonists as agents for lowering intraocular pressure |
US5698733A (en) | 1994-09-30 | 1997-12-16 | Alcon Laboratories, Inc. | Use of 9-deoxy prostaglandin derivatives to treat glaucoma |
AU7672096A (en) | 1995-06-07 | 1998-06-03 | Alcon Laboratories, Inc. | Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy |
US5866602A (en) | 1995-12-22 | 1999-02-02 | Alcon Laboratories, Inc. | Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives |
US5814660A (en) | 1995-12-22 | 1998-09-29 | Alcon Laboratories, Inc. | 9-oxa prostaglandin analogs as ocular hypotensives |
DE69633136T2 (de) | 1995-12-22 | 2005-09-01 | Alcon Laboratories, Inc., Fort Worth | Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel |
US5798380A (en) | 1996-02-21 | 1998-08-25 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
US6586425B2 (en) | 1996-02-21 | 2003-07-01 | Wisconsin Alumni Research Foundation | Cytoskeletal active agents for glaucoma therapy |
DE69714274T3 (de) | 1996-09-17 | 2006-06-01 | Asahi Glass Co., Ltd. | Fluorierte prostaglandinderivate und medikamente |
AU5436198A (en) | 1996-11-12 | 1998-06-03 | Alcon Laboratories, Inc. | 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension |
WO1998020881A1 (en) | 1996-11-12 | 1998-05-22 | Alcon Laboratories, Inc | 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension |
US6235779B1 (en) | 1996-11-12 | 2001-05-22 | Alcon Laboratories, Inc. | Use of cis-Δ4 analogs of prostaglandins as ocular hypotensives |
DE69705421T2 (de) | 1996-11-12 | 2002-05-16 | Alcon Lab Inc | 15-fluoro-prostaglandine als augendrucksenkende mittel |
CA2276666A1 (en) | 1997-03-07 | 1998-09-11 | Alcon Laboratories, Inc. | 13-thia prostaglandins for use in glaucoma therapy |
AU725677B2 (en) | 1997-05-09 | 2000-10-19 | Mount Sinai School Of Medicine Of The City University Of New York, The | 8-iso-prostaglandins for glaucoma therapy |
US5891646A (en) | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
SE9702706D0 (sv) | 1997-07-11 | 1997-07-11 | Pharmacia & Upjohn Ab | Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma |
PL339221A1 (en) | 1997-09-09 | 2000-12-04 | Procter & Gamble | Aromatic c16-c20-substituted tetrahydroprostaglandines useful as fp agonists |
CN1269786A (zh) | 1997-09-09 | 2000-10-11 | 普罗克特和甘保尔公司 | 用作fp激活剂的芳香族c16-c20-取代四氢前列腺素 |
NZ503736A (en) | 1997-09-09 | 2002-06-28 | Procter & Gamble | Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists |
US5877211A (en) | 1997-11-21 | 1999-03-02 | Allergan | EP2 receptor agonists as neuroprotective agents for the eye |
AU1709699A (en) | 1997-12-22 | 1999-07-12 | Alcon Laboratories, Inc. | 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension |
CA2295512C (en) | 1998-07-14 | 2009-05-26 | Alcon Laboratories, Inc. | Prostaglandin product |
TWI249520B (en) | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
US6720175B1 (en) | 1998-08-18 | 2004-04-13 | The Johns Hopkins University School Of Medicine | Nucleic acid molecule encoding homer 1B protein |
US20020065296A1 (en) | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
JP2003500385A (ja) | 1999-05-24 | 2003-01-07 | コア・セラピューティクス,インコーポレイテッド | Xa因子阻害剤 |
AU5413600A (en) | 1999-06-14 | 2001-01-02 | Eli Lilly And Company | Compounds |
CN1391469B (zh) | 1999-11-26 | 2010-05-26 | 盐野义制药株式会社 | Npy y5拮抗剂 |
ES2246922T3 (es) | 1999-12-28 | 2006-03-01 | Eisai Co., Ltd. | Compuestos heterociclicos que tienen grupos de sulfonamida. |
YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
HN2001000008A (es) | 2000-01-21 | 2003-12-11 | Inc Agouron Pharmaceuticals | Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo |
CA2399001C (en) | 2000-02-03 | 2010-07-20 | Eisai Co., Ltd. | Integrin expression inhibitor |
US6362177B1 (en) | 2000-05-16 | 2002-03-26 | Teijin Limited | Cyclic amine derivatives and their use as drugs |
US6908741B1 (en) | 2000-05-30 | 2005-06-21 | Transtech Pharma, Inc. | Methods to identify compounds that modulate RAGE |
US6323228B1 (en) | 2000-09-15 | 2001-11-27 | Abbott Laboratories | 3-substituted indole angiogenesis inhibitors |
DE60141849D1 (de) | 2000-10-17 | 2010-05-27 | Merck Serono Sa Coinsins | Pharmazeutisch aktive sulfonamid-derivate |
US7163800B2 (en) | 2000-11-03 | 2007-01-16 | Molecular Devices Corporation | Methods of screening compositions for G protein-coupled receptor desensitization inhibitory activity |
AU2002245590B2 (en) | 2001-03-05 | 2006-06-29 | Transtech Pharma, Inc. | Benzimidazole derivatives as therapeutic agents |
EP1379505B1 (en) | 2001-04-20 | 2007-02-28 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
WO2003059913A1 (en) | 2002-01-10 | 2003-07-24 | Bayer Healthcare Ag | Roh-kinase inhibitors |
TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
AU2003245773A1 (en) | 2002-02-15 | 2003-09-04 | Glaxo Group Limited | Vanilloid receptor modulators |
WO2003073999A2 (en) | 2002-03-01 | 2003-09-12 | Pintex Pharmaceuticals, Inc. | Pini-modulating compounds and methods of use thereof |
CN101597262A (zh) | 2002-03-05 | 2009-12-09 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
US7645878B2 (en) | 2002-03-22 | 2010-01-12 | Bayer Healthcare Llc | Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof |
DE60325719D1 (de) | 2002-05-13 | 2009-02-26 | Molecular Devices Corp | Konstitutiv translozierende zelllinie |
ES2382733T3 (es) | 2002-08-29 | 2012-06-13 | Santen Pharmaceutical Co., Ltd. | Remedio para el glaucoma que comprende un inhibidor de la Rho quinasa y prostaglandinas |
JPWO2004022753A1 (ja) | 2002-08-30 | 2005-12-22 | アンジェスMg株式会社 | アクチン関連新規細胞骨格タンパク質lacs |
EP1550660A1 (en) | 2002-09-12 | 2005-07-06 | Kirin Beer Kabushiki Kaisha | Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same |
US7495016B2 (en) * | 2002-10-21 | 2009-02-24 | Irm Llc | Pyrrolidones with anti-HIV activity |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
CA2526387A1 (en) | 2003-06-12 | 2004-12-23 | Astellas Pharma Inc. | Benzamide derivative or salt thereof |
JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス, インコーポレイテッド | c−Kit調節因子および使用方法 |
EP1689393A4 (en) | 2003-10-06 | 2008-12-17 | Glaxo Group Ltd | PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS |
TWI344961B (en) | 2003-10-15 | 2011-07-11 | Ube Industries | Novel indazole derivative |
JP2007008816A (ja) | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
SE0400284D0 (sv) | 2004-02-10 | 2004-02-10 | Astrazeneca Ab | Novel compounds |
JP2005227441A (ja) | 2004-02-12 | 2005-08-25 | Konica Minolta Medical & Graphic Inc | 光熱写真画像形成材料 |
US7592357B2 (en) | 2004-02-20 | 2009-09-22 | Smithkline Beecham Corporation | Compounds |
US20080096238A1 (en) | 2004-03-30 | 2008-04-24 | Alcon, Inc. | High throughput assay for human rho kinase activity with enhanced signal-to-noise ratio |
DE102004017438A1 (de) | 2004-04-08 | 2005-11-03 | Bayer Healthcare Ag | Hetaryloxy-substituierte Phenylaminopyrimidine |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
WO2006009889A1 (en) | 2004-06-17 | 2006-01-26 | Smithkline Beecham Corporation | Novel inhibitors of rho-kinases |
ES2535364T3 (es) | 2004-06-18 | 2015-05-08 | Tobii Ab | Control ocular de aparato informático |
RS51362B (en) | 2004-08-26 | 2011-02-28 | Pfizer Inc. | ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS |
JP4478157B2 (ja) | 2004-10-13 | 2010-06-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ヒドラジド誘導体 |
UY29198A1 (es) | 2004-11-09 | 2006-05-31 | Cancer Rec Tech Ltd | Derivados sustituidos de quinazolinona y derivados sustituidos de quinazolina-2, 4-diona, composiciones conteniéndolos, procedimientos de preparación y aplicaciones |
GB0425026D0 (en) | 2004-11-12 | 2004-12-15 | Biofocus Discovery Ltd | Compounds which bind to the active site of protein kinase enzymes |
CA2589271A1 (en) | 2004-12-07 | 2006-06-15 | Locus Pharmaceuticals, Inc. | Urea inhibitors of map kinases |
CA2593718A1 (en) | 2004-12-31 | 2007-05-31 | Gpc Biotech Ag | Napthyridine compounds as rock inhibitors |
US7652041B2 (en) | 2005-01-14 | 2010-01-26 | Millennium Pharmaceuticals, Inc. | Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity |
KR100896889B1 (ko) * | 2005-01-28 | 2009-05-14 | 아이알엠 엘엘씨 | 페닐-치환 피롤리돈 |
EP1851197A2 (en) | 2005-02-09 | 2007-11-07 | Microbia, Inc. | Phenylazetidinone derivatives |
BRPI0610142A2 (pt) | 2005-05-25 | 2011-01-04 | Wyeth Corp | método para preparar um composto da fórmula (i) ; e método para preparar um ácido da fórmula (vii) |
US20070135499A1 (en) | 2005-07-11 | 2007-06-14 | Aerie Pharmaceuticals, Inc. | Hydrazide compounds |
EP1910297B1 (en) | 2005-07-11 | 2016-05-25 | Aerie Pharmaceuticals, Inc. | Isoquinoline compounds |
EP2111863B1 (en) | 2005-10-26 | 2012-03-28 | Asahi Kasei Pharma Corporation | Fasudil in combination with bosentan for the treament of pulmonary arterial hypertension |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
RU2008130111A (ru) | 2005-12-22 | 2010-01-27 | Алькон Рисерч, Лтд. (Us) | (индазол-5-ил)пиразины и (1,3-дигидроиндол-2-он)пиразины для лечения опосредованнызх rно-киназой заболеваний и состояний |
AR057252A1 (es) | 2005-12-27 | 2007-11-21 | Alcon Mfg Ltd | Inhibicion de rho quinasa mediada por arni para el tratamiento de trastornos oculares |
EP1968940B1 (en) | 2005-12-30 | 2014-04-02 | Novartis AG | 3 , 5-substitued piperidine compounds as renin inhibitors |
KR101452520B1 (ko) | 2006-01-27 | 2014-10-21 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 피롤로[3,2-c]피리딘-4-온 2-인돌린온 단백질 키나제 억제제 |
JP5476559B2 (ja) | 2006-02-10 | 2014-04-23 | 国立大学法人九州大学 | リン酸化酵素の新規基質ポリペプチド |
EP1991531A1 (en) | 2006-02-28 | 2008-11-19 | Amgen Inc. | Cinnoline and quinoxaline derivates as phosphodiesterase 10 inhibitors |
JP2007246466A (ja) | 2006-03-17 | 2007-09-27 | Osaka Univ | 中枢神経損傷に対する嗅粘膜移植にRhoキナーゼ阻害剤を用いた神経機能再建法 |
TW200815398A (en) | 2006-06-08 | 2008-04-01 | Ube Industries | A novel indazole derivative having spirocyclic structure in the side chain |
WO2008036459A2 (en) | 2006-07-20 | 2008-03-27 | Borchardt Allen J | Inhibitors of rho kinase |
BRPI0713187A2 (pt) | 2006-07-20 | 2012-10-16 | Mehmet Kahraman | método de inibir rho-quinase, método de tratamento de doença mediada por rho-quinase, composto e composição farmacêutica |
CN101495117B (zh) | 2006-07-31 | 2012-08-15 | 千寿制药株式会社 | 含酰胺化合物的水性液体制剂 |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
WO2008044700A1 (fr) * | 2006-10-11 | 2008-04-17 | Takeda Pharmaceutical Company Limited | INHIBITEUR DE LA GSK-3β |
US8949825B1 (en) | 2006-10-17 | 2015-02-03 | Manageiq, Inc. | Enforcement of compliance policies in managed virtual systems |
US20090036465A1 (en) | 2006-10-18 | 2009-02-05 | United Therapeutics Corporation | Combination therapy for pulmonary arterial hypertension |
WO2008049919A2 (en) | 2006-10-26 | 2008-05-02 | Devgen N.V. | Rho kinase inhibitors |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
WO2008079945A2 (en) | 2006-12-20 | 2008-07-03 | University Of South Florida | Rock inhibitors and uses thereof |
AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
JP5318779B2 (ja) | 2006-12-27 | 2013-10-16 | サノフイ | シクロアルキルアミン置換イソキノリン及びイソキノリノン誘導体 |
EP2132194B1 (en) | 2006-12-27 | 2011-03-16 | Sanofi-Aventis | Substituted isoquinolines and their use as rho-kinase inhibitors |
EP2125745B1 (en) | 2006-12-27 | 2017-02-22 | Sanofi | Cycloalkylamine substituted isoquinolone derivatives |
JP5405315B2 (ja) | 2006-12-27 | 2014-02-05 | サノフイ | 置換イソキノリン及びイソキノリノン誘導体 |
EP2102187B1 (en) | 2006-12-27 | 2015-04-01 | Sanofi | Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase |
ATE505458T1 (de) | 2006-12-27 | 2011-04-15 | Sanofi Aventis | Cycloalkylaminsubstituierte isochinolon- und isochinolinonderivate |
ATE554072T1 (de) | 2006-12-27 | 2012-05-15 | Sanofi Sa | Cycloalkylaminsubstituierte isochinolinderivate |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
CA2683647A1 (en) | 2007-04-10 | 2008-10-16 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
NZ582692A (en) | 2007-07-05 | 2012-05-25 | Array Biopharma Inc | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
NZ585980A (en) * | 2007-11-16 | 2012-04-27 | Vertex Pharma | Isoquinoline modulators of atp-binding cassette transporters |
US8455514B2 (en) | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
DK2315591T3 (en) | 2008-08-15 | 2016-06-06 | Nivalis Therapeutics Inc | NOVEL PYRROLE INHIBITORS OF S-nitrosoglutathione-reductase as therapeutic agents |
CA2760562C (en) | 2009-05-01 | 2016-07-19 | Aerie Pharmaceuticals, Inc. | Dual mechanism inhibitors for the treatment of disease |
MX2011013857A (es) | 2009-06-19 | 2012-01-30 | Western Therapeutics Inst Inc D | Derivado sustituido de isoquinolina. |
WO2011085351A2 (en) | 2010-01-11 | 2011-07-14 | The Johns Hopkins University | Method of treating kcnq related disorders |
EP2663553B1 (en) | 2010-09-01 | 2015-08-26 | Ambit Biosciences Corporation | Quinoline and isoquinoline derivatives for use as jak modulators |
RU2013117209A (ru) | 2010-11-08 | 2014-10-27 | Хилор Лтд. | Буферные глазные композиции и способы их применения |
TW201729813A (zh) | 2011-02-04 | 2017-09-01 | Kowa Co Ltd | 青光眼預防或治療之藥物療法 |
EP2671883A1 (en) | 2012-06-05 | 2013-12-11 | Bioprojet | New 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands |
CN104884432A (zh) | 2012-08-01 | 2015-09-02 | 默沙东公司 | α7烟碱乙酰胆碱受体调节剂及其用途-I |
US9751885B2 (en) * | 2012-10-12 | 2017-09-05 | Takeda Pharmaceutical Company Limited | Cyclopropanamine compound and use thereof |
CN105263494A (zh) | 2013-03-15 | 2016-01-20 | 爱瑞制药公司 | 联合治疗 |
WO2016009076A1 (en) | 2014-07-17 | 2016-01-21 | Merck Patent Gmbh | Novel naphthryidines and isoquinolines and their use as cdk8/19 inhibitors |
US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US9770466B2 (en) | 2015-07-02 | 2017-09-26 | Veloce Biopharma, Llc | Ophthalmic composition and methods of use |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
US9963432B2 (en) | 2016-08-19 | 2018-05-08 | Aerie Pharmaceuticals, Inc. | Beta-amino-isoquinolinyl amide compounds |
BR112019003945A2 (pt) | 2016-08-31 | 2019-05-21 | Aerie Pharmaceuticals, Inc. | composições oftálmicas |
CN110506037A (zh) | 2017-03-31 | 2019-11-26 | 爱瑞制药公司 | 芳基环丙基-氨基-异喹啉酰胺化合物 |
US20190322625A1 (en) | 2018-03-30 | 2019-10-24 | Aerie Pharmaceuticals, Inc. | Mono-(acid) salts of 6-aminoisoquinolines and uses thereof |
WO2020056345A1 (en) * | 2018-09-14 | 2020-03-19 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
-
2018
- 2018-03-30 CN CN201880021623.3A patent/CN110506037A/zh active Pending
- 2018-03-30 SG SG11201908179U patent/SG11201908179UA/en unknown
- 2018-03-30 US US15/941,993 patent/US10858339B2/en active Active
- 2018-03-30 EP EP18776337.0A patent/EP3609871A4/en active Pending
- 2018-03-30 JP JP2019553272A patent/JP2020515583A/ja active Pending
- 2018-03-30 MX MX2019011784A patent/MX2019011784A/es unknown
- 2018-03-30 CA CA3057872A patent/CA3057872A1/en active Pending
- 2018-03-30 WO PCT/US2018/025494 patent/WO2018183911A1/en unknown
- 2018-03-30 AU AU2018243687A patent/AU2018243687C1/en active Active
- 2018-03-30 BR BR112019020078A patent/BR112019020078A2/pt not_active Application Discontinuation
- 2018-03-30 KR KR1020197031763A patent/KR20190135027A/ko unknown
-
2020
- 2020-07-22 US US16/936,257 patent/US11312700B2/en active Active
- 2020-10-06 AU AU2020250183A patent/AU2020250183A1/en not_active Abandoned
-
2022
- 2022-04-18 US US17/722,832 patent/US20230130470A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20190135027A (ko) | 2019-12-05 |
AU2018243687B2 (en) | 2020-07-09 |
CA3057872A1 (en) | 2018-10-04 |
AU2018243687A1 (en) | 2019-09-26 |
US11312700B2 (en) | 2022-04-26 |
SG11201908179UA (en) | 2019-10-30 |
US20210002253A1 (en) | 2021-01-07 |
US20230130470A1 (en) | 2023-04-27 |
US10858339B2 (en) | 2020-12-08 |
WO2018183911A1 (en) | 2018-10-04 |
AU2020250183A1 (en) | 2020-11-05 |
CN110506037A (zh) | 2019-11-26 |
US20180327381A1 (en) | 2018-11-15 |
AU2018243687C1 (en) | 2020-12-24 |
JP2020515583A (ja) | 2020-05-28 |
EP3609871A1 (en) | 2020-02-19 |
EP3609871A4 (en) | 2021-01-06 |
BR112019020078A2 (pt) | 2020-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019011784A (es) | Compuestos de aril ciclopropil-amino-isoquinolinil amida. | |
MX2019002019A (es) | Compuestos de beta-amino-isoquinolinil amida. | |
MX2017004234A (es) | Inhibidor del egfr y preparacion y aplicacion del mismo. | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2021001186A (es) | Purinonas como inhibidores de proteasa especifica de ubiquitina 1. | |
MX2021002220A (es) | Forma cristalina de base libre de lorlatinib. | |
WO2015073587A3 (en) | Synthetic membrane-receiver complexes | |
WO2016029191A3 (en) | Channel modulators | |
MX2022000754A (es) | Composiciones y metodos de uso de nintedanib para tratar enfermedades oculares con neovascularizacion anormal. | |
NZ732799A (en) | Picolinamides with fungicidal activity | |
EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
PE20160875A1 (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
WO2010011853A3 (en) | Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | |
MY198613A (en) | Nitrobenzyl derivatives of anti-cancer agents | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
MX2015012431A (es) | Pirrol amida como inhibidores. | |
PH12016501702B1 (en) | Pyrazole amide derivative | |
PH12018500047B1 (en) | Notch pathway signaling inhibitor compounds | |
WO2016077639A3 (en) | Nanovesicular therapies | |
MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
MY186271A (en) | Ophthalmic compositions and methods of use therefor | |
GEP20196950B (en) | Imidazopyridazine compounds | |
MX2020006596A (es) | Hidroxiisoxazolinas y derivados de estos. | |
MX2016014436A (es) | Derivados de heterociclil-butanamida. | |
WO2016176620A8 (en) | Extracellular matrix compositions for the treatment of cancer or immunological diseases |